TrialBMC cancer2021

Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.

Zaisheng Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.